Free Trial

KalVista Pharmaceuticals (KALV) Insider Trading & Ownership

KalVista Pharmaceuticals logo
$8.96 -0.09 (-0.99%)
(As of 11/20/2024 ET)

KalVista Pharmaceuticals (NASDAQ:KALV) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
10.50%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$5.81 M
Number Of
Insiders Selling
(Last 12 Months)
5
Amount Of
Insider Selling
(Last 12 Months)
$2.97 M
Get KALV Insider Trade Alerts

Want to know when executives and insiders are buying or selling KalVista Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

KALV Insider Buying and Selling by Quarter

KalVista Pharmaceuticals Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2024Benjamin L PalleikoCEOSell14,400$9.26$133,344.00  
11/18/2024Paul K AudhyaInsiderSell8,077$9.26$74,793.02  
9/9/2024Benjamin L PalleikoCEOSell7,352$12.19$89,620.88  
8/23/2024Paul K AudhyaInsiderSell2,135$12.40$26,474.00  
8/19/2024Benjamin L PalleikoCEOSell14,215$12.01$170,722.15  
8/19/2024Christopher YeaInsiderSell7,102$12.01$85,295.02  
6/7/2024Benjamin L PalleikoCEOSell7,465$11.53$86,071.45  
5/20/2024Benjamin L PalleikoCEOSell21,959$11.76$258,237.84  
5/20/2024Edward P FeenerInsiderSell8,088$11.76$95,114.88  
2/20/2024Benjamin L PalleikoCFOSell22,802$14.11$321,736.22  
2/20/2024Edward P FeenerInsiderSell28,288$14.07$398,012.16  
2/20/2024Thomas Andrew CrockettCEOSell24,888$14.11$351,169.68  
2/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy29,747$14.70$437,280.90  
2/6/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,474$14.74$65,946.76  
1/29/2024Venrock Healthcare Capital ParMajor ShareholderBuy80,600$14.22$1,146,132.00  
1/26/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,174$12.98$54,178.52  
1/24/2024Venrock Healthcare Capital ParMajor ShareholderBuy20,686$12.44$257,333.84  
1/22/2024Venrock Healthcare Capital ParMajor ShareholderBuy67,546$12.55$847,702.30  
1/18/2024Venrock Healthcare Capital ParMajor ShareholderBuy39,680$12.51$496,396.80  
1/16/2024Venrock Healthcare Capital ParMajor ShareholderBuy19,599$12.73$249,495.27  
1/11/2024Edward P FeenerInsiderSell22,679$13.03$295,507.37  
1/10/2024Venrock Healthcare Capital ParMajor ShareholderBuy47,700$12.67$604,359.00  
1/8/2024Edward P FeenerInsiderSell17,221$13.01$224,045.21  
1/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy69,184$12.44$860,648.96  
1/3/2024Venrock Healthcare Capital ParMajor ShareholderBuy17,605$12.20$214,781.00  
12/29/2023Venrock Healthcare Capital ParMajor ShareholderBuy6,013$12.49$75,102.37  
12/27/2023Thomas Andrew CrockettCEOSell30,000$12.02$360,600.00  
12/27/2023Venrock Healthcare Capital ParMajor ShareholderBuy41,514$11.97$496,922.58  
(Data available from 1/1/2013 forward)

KALV Insider Trading Activity - Frequently Asked Questions

The list of insiders at KalVista Pharmaceuticals includes Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Paul K Audhya, Thomas Andrew Crockett, and Venrock Healthcare Capital Par. Learn more on insiders at KALV.

10.50% of KalVista Pharmaceuticals stock is owned by insiders. Learn more on KALV's insider holdings.

The following insider purchased KALV shares in the last 24 months: Venrock Healthcare Capital Par ($5,806,280.30).

Insiders have purchased a total of 448,522 KALV shares in the last 24 months for a total of $5,806,280.30 bought.

The following insiders have sold KALV shares in the last 24 months: Albert Cha ($189,000.00), Benjamin L Palleiko ($1,278,824.27), Christopher Yea ($111,699.58), Edward P Feener ($1,012,679.62), Paul K Audhya ($213,457.54), and Thomas Andrew Crockett ($979,768.94).

Insiders have sold a total of 317,968 KalVista Pharmaceuticals shares in the last 24 months for a total of $3,785,429.95 sold.

KalVista Pharmaceuticals Key Executives

  • Mr. Benjamin L. Palleiko (Age 58)
    CEO & Director
    Compensation: $983.07k
    4 recent trades
  • Dr. Christopher M. Yea Ph.D. (Age 60)
    Chief Development Officer
    Compensation: $708.53k
  • Dr. Paul K. Audhya M.B.A. (Age 51)
    M.D., Chief Medical Officer
    Compensation: $736.82k
  • Mr. Brian Piekos (Age 49)
    Chief Financial Officer
  • Mr. Ryan Baker
    Head of Investor Relations
  • Mr. Brian Krex J.D. (Age 56)
    General Counsel
  • Jarrod Aldom
    Vice President of Corporate Communications
  • Ms. Rachel M. Morten
    Senior Vice President of Regulatory Affairs & QA
  • Dr. Michael D. Smith Pharm.D. (Age 44)
    Senior Vice President of Development
  • Ms. Nicole Sweeny (Age 48)
    Chief Commercial Officer


This page (NASDAQ:KALV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners